financetom
Business
financetom
/
Business
/
Blackbaud Q2 Non-GAAP Earnings, Revenue Rise; 2024 Outlook Reaffirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blackbaud Q2 Non-GAAP Earnings, Revenue Rise; 2024 Outlook Reaffirmed
Jul 30, 2024 3:10 PM

05:42 PM EDT, 07/30/2024 (MT Newswires) -- Blackbaud ( BLKB ) reported Q2 non-GAAP earnings late Tuesday of $1.08 per diluted share, up from $0.98 a year earlier.

Analysts polled by Capital IQ expected $1.04.

Revenue for the quarter ended June 30 was $287.3 million, up from $271 million a year earlier. Analysts surveyed by Capital IQ expected $289 million.

The company reaffirmed its full-year 2024 non-GAAP EPS guidance of $4.12 to $4.38 on revenue of $1.16 billion to $1.19 billion. Analysts expect normalized EPS of $4.26 on revenue of $1.18 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Analysis-Mining industry struggles with valuation gap amid shift to copper
Analysis-Mining industry struggles with valuation gap amid shift to copper
Oct 2, 2024
LONDON (Reuters) - Leading mining companies are struggling to balance investor expectations for hefty returns with paying the necessary premiums to buy pure play copper companies as global demand for the metal sends valuations soaring. Big diversified miners including Rio Tinto, BHP Group ( BHP ) and Glencore ( GLCNF ), pressured by a slowdown in global economic growth and...
Top Premarket Decliners
Top Premarket Decliners
Oct 2, 2024
07:42 AM EDT, 09/27/2024 (MT Newswires) -- Aytu BioPharma ( AYTU ) shares slumped 19% pre-bell Friday after the company reported weaker fiscal Q4 financial results. Fenbo Holdings ( FEBO ) shares retreated 17%, erasing Thursday's rally. enVVeno Medical (NVNO) shares fell 16% after pricing a $15 million public offering of common shares and pre-funded warrants. Telesis Bio ( TBIO...
BMO on The Day Ahead in Canada
BMO on The Day Ahead in Canada
Oct 2, 2024
07:35 AM EDT, 09/27/2024 (MT Newswires) -- Canada's gross domestic product data for July and flash August at 8:30 a.m. ET Friday could have a major bearing on the size of the next rate cut by the country's central bank, said Bank of Montreal (BMO). Real GDP numbers for July and flash August will guide estimates for the quarter, noted...
Sanofi, Regeneron Pharmaceuticals Receive Chinese Regulator's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment
Sanofi, Regeneron Pharmaceuticals Receive Chinese Regulator's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment
Oct 2, 2024
07:38 AM EDT, 09/27/2024 (MT Newswires) -- Sanofi ( SNY ) and Regeneron Pharmaceuticals ( REGN ) said Friday that China's National Medical Products Administration has approved Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, or COPD, characterized by raised blood eosinophils. The companies said the approval particularly covers patients who are under treatment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved